# The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05426018` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05426018](<https://clinicaltrials.gov/study/NCT05426018>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05426018

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05426018. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-01 (anticipated); primary completion 2023-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05426018, source copy `cardio:ctgov-nct05426018-2022-06-21`, retrieved 2026-10-26)
- Planned start: 2022-07-01 (anticipated) (ClinicalTrials.gov record NCT05426018, source copy `cardio:ctgov-nct05426018-2022-06-21`, retrieved 2026-10-26)
- Primary completion: 2023-06-30 (anticipated) (ClinicalTrials.gov record NCT05426018, source copy `cardio:ctgov-nct05426018-2022-06-21`, retrieved 2026-10-26)
- Completion: 2023-10-01 (anticipated) (ClinicalTrials.gov record NCT05426018, source copy `cardio:ctgov-nct05426018-2022-06-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05426018, source copy `cardio:ctgov-nct05426018-2022-06-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05426018-2022-06-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): SY-009 capsules
- Lead sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 8b36e5c5aa2983de5f2a9f277bb6b251fdb0a06af10b03207ad10e22c3cfec00
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
